Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PART: Teplizumab in Psoriatic Arthritis
NCT00239720Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2006
- Primary completion
- Dec 2006
- Countries
- 1
01
Overview
A Phase 2 trial of teplizumab in psoriatic arthritis (PsA), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2006; status: terminated.
02
Drugs
teplizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT00239720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00239720.